US FDA Permits AliveCor's AI Mobile ECG To Measure QTc In COVID-19 Patients

 
• By Marion Webb

AliveCor wins US FDA permission to use its mobile ECG to detect heart problems caused by drugs to treat COVID-19 patients.

Heart disorder and atrial fibrillation ecg as a coronary cardiac attack with irregular and normal organ rhythm as a chest discomfort disease concept in a 3D illustration style.

More from Approvals

More from Policy & Regulation